Education and training


University of Kansas Medical Center



Download 352.96 Kb.
Page2/3
Date29.01.2017
Size352.96 Kb.
#11537
1   2   3

University of Kansas Medical Center:

Courses and Academic Lectures:

1987 Drug Metabolism and Disposition, Graduate Students, 8 students, 1 - two hour lecture.



Toxicology, Graduate Students, 8 students, 2 - one hour lectures.

1988 Nursing Pharmacology (Blood and Endocrine Unit) 100 nursing students, 7-one hour lectures.

1989 Medical Pharmacology (Consultant to 19 students) 170 students, 1 semester, medical students.

Drug Metabolism and Disposition, Graduate students, 10 students, 1-two hour lecture.

Toxicology, Graduate Students, 10 students, 2-two

hour lectures.

1990 Medical Pharmacology, (Consultant to 21 students) 160 students and gave 2-one hour lectures, medical students.

Advanced Toxicology, graduate students,

10 students,gave 1- two hour lecture.



Cellular and Molecular Pharmacology, 13 Graduate students, gave 2-two hour lectures.

1991 Medical Pharmacology, 165 medical students, gave 1- one hour lecture.



Toxicology, University of Missouri, Department of Pharmacology and Toxicology, 3-one hour lectures to 8 graduate students.
Guidance of Graduate Students and Postdoctoral Fellows (Kansas):

Directed the Ph.D. thesis of two graduate students:

Edwin O. Nuzum: graduated with Ph.D., August 15, 1990.

Laurie A. Hanson: graduated with Ph.D., April 16, 1992.

Supervised the following postdoctoral fellow:

Kurt A. Droms, Ph.D. 1990 - 1991.


Supervised the research training of the following graduate students during research rotations (4-6 months) in my laboratory:

Aida Howell 1987

Laurie Pan 1988

Monty Eberhart 1988

Angela Hahn 1989

Robin Pearse 1989

Clarissa Haugness 1990

Jennifer Wagner 1991


Universities of Colorado and Wisconsin:

Courses and Academic Lectures:

1980-1981 Co-instructor of Pathology Course, School of Pharmacy Students,University of Colorado, 80 students, 1 semester course. I gave eight one hour lectures




COMMITTEE AND ADMINISTRATIVE SERVICES

University of Michigan:

1992 Cancer Center Committee for Animal Care Facility.

1993 Department of Surgery, Molecular Biology Program Planning Committee.

1991-present Director, Thoracic Surgery Tumor Biology Laboratory.

1993-2001 Department of Surgery, Research Advisory Committee.

2000 Lung Cancer Advisory Committee, State of Michigan.

2001-2004 Biomedical Research Advisory Council (BMRC).
University of Kansas Medical Center:

Member of Speas Foundation Cancer Review Board, 1987.

Member, American Cancer Society Small Grant Review Board, 1987, 1989-90.

Co-organizer of Department Journal Club, 1988 - 1991.

Member Radiation Safety Committee, 1989 - 1991.

Member University of Kansas Travel Committee, 1989 - 1991.

Member Department of Pharmacology Graduate Committee, 1988-1990.

Member Flossie West Cancer Grant Review Board, 1990.



Dissertation: Biochemical and Histochemical Studies on the Regulation of

Normal and Neoplastic Lung Development, 1984.



CONSULTING POSITIONS

2004 External Scientific Advisor, Vanderbilt University Lung Spore

2005 External Advisory Committee, NYU Cancer Center

2008 Advisory committee for CR-UK strategic workshop on esophageal cancer, March 2008

2008 External Scientific Advisor, Washington University Lung Spore

2010 External Advisory Committee, University of Minnesota Cancer Center



Extramural Invited Presentations

University of Michigan

October 14, 1992, "Molecular Biology of Esophageal Cancer-Implications for New Prognostic Factors", American College of Surgeons Annual Clinical Congress, New Orleans, LA.

March, 1993, "Methods for Allelic-Specific Gene Expression", Society for Toxicology Annual Meeting, New Orleans, LA.

April, 1993, Thoracic Surgery Biology Club, "Intestinal Differentiation in Barrett's Esophagus", Meeting of the American Association for Thoracic Surgery, Chicago, IL.

June 24, 1994, Lyman A. Brewer Lecture, Esophageal Cancer: From Molecular Biology to Esophagectomy", The Western Thoracic Surgical Association, Squaw Creek, CA.

October 21, 1994. The Ohio State University, Department of Preventative Medicine, "Role of Intestinal Differentiation in Esophageal Cancer".

April 28, 1996. American Assoc. Thoracic Surgery, San Diego CA. Invited Lecture.

November 22, 1996. American Cancer Society Seventh Annual Meeting, Invited Speaker.

January 15, 1998, Wayne State University. Genetic Alterations in Esophageal Cancer. Invited Lecture.

May 22, 1998, Department of Surgery Research Seminar, "New Experimental Approaches to Study Barrett's Adenocarcinoma".

September 27, 1998. Boston Barrett’s Symposium. “Chemoprevention of Barrett’s Metaplasia”

March 26, 1999, University of Michigan Cancer Center Grand Rounds. “Esophageal Cancer”.

May 4, 1999, Division of Nephrology, University of Michigan. “Gene Amplification Events in Barrett's Adenocarcinoma".

June 23, 1999, Axys Pharmaceuticals, San Diego CA, “Barrett’s Metaplasia and the Identification of Genes Associated with Esophageal Adenocarcinoma Development”.

August, 1999, Monsanto, St. Louis, MO.“Identification of Genes Associated with Esophageal Adenocarcinoma Development”.

December 1999. Organogenesis Center Symposium“Origins of Barrett’s metaplasia”

March 9, 2000, Eppley Cancer Institute, University of Nebraska. “Identification of novel gene amplification events in esophageal adenocarcinoma.”

Sept 3, 2000 6th OESO Conference on Barrett Esophagus, Paris, France: What is the in vivo value of chromosomal 9p21 allelic loss and CDKN2 gene mutation in detecting neoplastic progression before aneuploidy and cancer?

October 27, 2000, “Esophageal Cancer Genetics”, American College of Surgeons meeting, Chicago, IL.

February 16, 2001, Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo,"Barrett's Metaplasia: Risk Factors and Genetic Alterations Associated with Adenocarcinoma Development".

February 23, 2001, “Gene expression profiles define a high-risk group among patients with stage I lung adenocarcinomas”, Department of Surgery, University of Michigan.

March 9, 2001, General Thoracic Surgical Club, Captiva Island Florida, two lectures “The human genome project: Implications for Thoracic surgery”, Use of molecular profiling for assessing patient prognosis in thoracic neoplasms”.

March 24, 2001, “Gene expression profiles define a high-risk group among patients with stage I lung adenocarcinomas”, Tumor vaccine and cell therapy working group meeting, New Orleans, LA.

April 19, 2001, “Microarray analysis of lung cancer”, Wayne State, Institute of Chemical Toxicology, MI.

September 6, 2001, “Molecular Analysis of Lung Cancer using Genomics and Proteomics”, Central Society for Clinical Research, Chicago Il.

October 16, 2001, Proteomic Analysis of Lung Adenocarcinomas, EDRN Seattle WA.

November 8, 2001, “Molecular Profiling of Lung Cancer” Director’s Challenge Meeting, Bethesda MD.

November 14, 2001, “Gene and Proteomic Profiling for Predicting Patient Survival in Early Stage Lung Cancer”, Cellular and Molecular Biology Department, University of Michigan.

January 7, 2002, “Gene Expression Analysis of Lung Cancer”, Lung Spore Meeting, Denver CO.

January 14, 2002, “Gene and Protein Profiling of Lung Adenocarcinoma”, Department of Pathology, University of Michigan.

February 19, 2002, Seminar presentation at Pharmacia Co., St. Louis MO.

March 12, 2002, Gordon Conference on New Frontiers in Cancer Detection and Diagnosis.

April 2, 2002, University of Kansas Cancer Center, two invited talks, Cancer Center and Department of Pharmacology, Toxicology and Therapeutics.

April 6, 2002, AACR, San Franscisco, CA.

April 18, 2002, NCI-Frederick MD.

April 30, 2002 Affymetrix Working Group Meeting, Chicago Il.

May 6, 2002, NCI, Directors Challenge Presentation, Washington, DC.

June 5, 2002, Quebec City, Quebec.

June 6, 2002, Montreal, Quebec.

June 27, 2002, NCI/EORTC presentation, Washington DC.

November 19, 2002, Dept. of Pathology, University of Pittsburgh.

January 30, 2003, School of Pharmacy, University of Colorado, Denver, CO.

March 2, 2003, Tumor Markers:Discovery to Practice, Santa Barbara, CA.

March 29, 2003, Current Trends in Lung Cancer, Houston, TX.

April 19, 2003, Johnson and Johnson Co., La Jolla CA.

May 13, 2003, Cambridge Healthtech Institute’s Macroresults for Microarrays, Boston, MA.

May 17, 2003, American Thoracic Society, Lung Proteomics Post-Graduate Course, Seattle WA.

June 27, 2003, Lung Cancer Conference, Maui, HI.

Oct 31, 2003, Keynote Speaker 3rd International Early Lung Cancer Detection Workshop, Liverpool UK.

November 13, 2003, CAMDA Keynote Speaker, Duke University, NC.

November 17, 2003, Speaker ACOS, Seoul Korea.

December 4, 2003, Ohio State University.

February 20, 2004, Targeted Therapies for the Treatment of Lung Cancer Meeting, Highlight Topic Speaker, San Diego CA.

May 14, 2004, Messina Conference on Cancer Pharmacogenomics, Sicili, Italy.

June 21, 2004, Barrett’s Chemoprevention Symposium, New York, NY.

July 3, 2004, 5th International Lung Cancer Congress, Kauai, HI.

October 8, 2004, University of Michigan Bioinformatics Program

November 4, 2004, Directors Challenge Meeting Bethesda, MD

November 6, 2004, Consensus Conference on BAC, New York NY

November 12, 2004, Department of Surgery Research Seminar, University of Michigan

February 11, 2005, Proteomic analyses in lung cancer, Targeted Therapies for the treatment of lung cancer, Steamboat Springs, CO.

February 26, 2005, Molecular staging of lung cancer, AACR Special Conference, San Diego CA.

July 4, 2005, Expression profiling of lung cancer, IASLC meeting, Barcelona, Spain.

Oct 27, 2005, Keynote Speaker, 4th International Early Lung Cancer Detection Workshop, Liverpool UK.

November 11, 2005, Lung Cancer: A translational focus, Washington DC

December 2, 2005, Washington University School of Medicine, St. Louis MO

December 9, 2005, Symposium on management of early lung cancer, Vancouver BC

January 25, 2006, Lung Spore Meeting, LA California

February 2, 2006, EDRN Meeting Washington DC

February 7, 2006, University of Minnesota Cancer Center, Minneapolis MN

March 1, 2006, Department of Surgery Grand Rounds, West Virginia University, School of Medicine, Morganstown WV.

March 1, 2006, Cell and Molecular Biology Seminar Series, West Virginia University Cancer Center, Morganstown WV.

October 14, 2006, 11th World Congress on Advances in Oncology, Crete, Greece

November 30, 2006, Ontario Cancer Institute, Toronto, Canada

March 13, 2007, JCA-AACR Special Joint Conference, Nagoya, Japan

April 14, 2007, AACR Annual Meeting, Los Angeles, CA.

September 4, 2007, 12th World Conference on Lung Cancer, Seoul, Korea

September 15, 2007, 7th Annual Lung Cancer Symposium, University of Cincinnati

October 14, 2007, 3rd Haifa Cancer Prevention Workshop, Haifa, Isreal

December 6th, 2007, Karmanos Cancer Institute, Detroit MI

April 23-26 2008, ESMO-IASLC meeting, Geneva, Switzerland

July 10, 2008, 1st International Lung Conference, Liverpool, UK

October 22, 2008, Department of Surgery, UM

December 4, 2008, SPECs meeting, Vanderbilt TN

March 6, 2009, SSO Pheonix AZ

May 29, 2009, National Lung Cancer Partnership Meeting, Orlando FL

August 4, 2009, 13th World Conference on Lung Cancer, San Francisco CA

November 1, 2009, 19th Hiroshima Lung Cancer Conference, Hiroshima, Japan

November 17, 2009: Division of Gastroenterology, University of Michigan, Ann Arbor

December 3, 2009, Editors, Nature Journals Advisory Committee, New York, NY

February 6, 2010: Lung Cancer Study Group, Barcelona, Spain

February 9, 2010, Nature Meeting on Systems Biology and HIV, Atlanta, GA.

February 19, 2010, Critical Issues in Lung Cancer, Stockholm, SE

February 25, 2010, Targeted Therapies in Lung Cancer, Santa Monica, CA.

March 8, 2010: University of Michigan Hematology/Oncology Seminar Series

April 7, 2010: Translational Research in Medicine Seminar Series, UMCCC

May 17, 2010: ATS Meeting, New Orleans LA

October 6, 2010, University of Michigan Epigenetic Cancer Seminar Series

October 28, 2010, NFGC Meeting, Clearwater FL

November 15, 2010, Celgene Advisory Meeting, Zurich, Switzerland

March 9, 2011, Cell and Developmental Biology, University of Michigan

March 10, 2011, Hematology and Oncology, Columbia University, NY

April 10, 2011, IASLC/ASCO/ECMO Targeted Therapy of Lung Cancer, Malta

October 20, 2011, Oncology Network for Excellence: MET, Falls Church VA

November 3, 2011, Esophageal Support Group, University of Michigan

January 9, 2012, AACR-IASLC, Molecular Origins of Lung Cancer, Plenary Lecture

March 10, 2012, Moffitt Cancer Center, Tampa FL

May 7, 2012, Memorial Sloan Kettering, NY, Grand Rounds and Thoracic Oncology Lecturer

May 11th 2012, BETRnet NCI, Bethesda MD

September 2, 2012, OSEO Como Italy

October 10 2012, University of Colorado, Denver

March 7, 2013, CONPO, Barcelona, Spain

July 8, 2013, BETRnet NCI, Bethesda MD
University of Kansas Medical Center

April 9, 1987, Kansas Cancer Research Conference, University of Kansas Medical Center, KS., "Proto-oncogene Expression in Preneoplastic and Neoplastic Liver Lesions".

November 30, 1988, Symposium on "Mouse Liver Carcinogenesis", Austin, TX., "Proto-oncogene and Gap-Junction Protein Expression in Rodent Liver Neoplasms".

September 28, 1989, Seminar at School of Basic Life Sciences, University of Missouri, Kansas City, MO., "Activation and Expression of the K-ras Oncogene in Murine Lung Tumors and Lung Tumor Cell Lines".

March 23, 1990, Symposium on "Mouse Lung Carcinogenesis" National Institutes of Environmental Health Sciences, Research Triangle Park, NC., "Expression of the Glucocorticoid Receptor and K-ras Genes in Urethan-induced Mouse Lung Tumors and Transformed Cell Lines".

May 9, 1990, Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI., "Role of K-ras Activation and Expression in Mouse Lung Carcinogenesis".

February 11, 1991, Invited to give a 3-hour series of lectures on "Oncogenes and Oncogenesis" in the Department of Pharmacology and Toxicology, University of Missouri at Kansas City, MO.
Universities of Colorado and Wisconsin

May 13, 1986, Department of Anatomy and Cell Biology, State University of New York, Syracuse, NY.

May 8, 1986, Department of Anatomy, University of California at San Francisco, CA.

June 20, 1986, Presentation at Symposium on "Mechanisms of Cellular Toxicity and Adaption", Northwestern University, Chicago,


PATENTS

Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexins and Autoantibodies used as Markers for Lung Cancer or Oesophageal Cancer. European Patent EP1200832A1, Awarded May 2, 2002.

Hanash S, Misek D, Hinderer R, Beer DG and Brichory F.: Annexin Proteins and Autoantibodies as Serum Markers for Cancer. US Patent 6,645,465, Awarded Nov 11, 2003.

Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Autoantibodies used as Markers for Lung Cancer. European Patent EP1734368A2, Awarded December 20, 2006.

Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexins as Markers for Lung or Esophageal Cancer. European Patent EP2051079A3, Awarded June 10, 2009.

Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Proteins and Autoantibodies as Serum Markers for Cancer. U.S. Patent 7,955,602, Awarded June 7, 2011.

Hanash S, Misek D, Hinderer R, Beer D and Brichory F: Annexin Proteins and Autoantibodies as Serum Markers for Cancer. U.S. Patent 7,759,081, Awarded July 27, 2010.

Beer DG, Kardia S, Giordano TJ, Taylor J, Hanash SM, Huang CC, Misek DE, Thomas D. and Kuick R: Expression Profile of Lung Cancer. Patent Application Filed.

Beer DG, Taylor J, G.Chen and Sinae Kim: Lung Cancer Signature. Patent Application Filed May 16, 2012.

BIBLIOGRAPHY

Peer-Reviewed Publications

1. Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Inhibition of rat liver aldehyde dehydrogenase by carbon tetrachloride. J Pharmacol Exp Ther 219: 821-826, 1981. PMID: 7299699

2. Beer DG, Hjelle JJ, Petersen DR, Malkinson AM: Ca2+-activated proteolytic activity in rat liver mitochondria. Biochem Biophys Res Comm 104:1276-1283, 1982. PMID: 6762879

3. Hjelle JJ, Grubbs JH, Beer DG, Petersen DR: Time course of the carbon tetrachloride-induced decrease in mitochondrial aldehyde dehydrogenase activity. Toxicol Appl Pharmacol 67: 159-165, 1983. PMID: 6836571

4. Beer DG, Cunha GR, Malkinson AM: Autoradiographic demonstration of the specific binding and nuclear localization of 3H-dexamethasone in adult mouse lung. Lab Invest 49: 725-734, 1983. PMID: 6656202

5. Beer DG, Butley MS, Malkinson AM: Developmental changes in the endogenous ca2+-stimulated proteolysis of mouse lung cAMP-dependent protein kinases. Arch Biochem Biophys 228: 207-219, 1984. PMID: 6320733

6. Butley MS, Beer DG, Malkinson AM: Functional changes in the regulatory subunit of the type II cyclic adenosine 3':5'-monophosphate-dependent protein kinase isozyme during normal and neoplastic lung development. Cancer Research 44: 2689-2697, 1984. PMID: 6327022

7. Beer DG, Malkinson AM: Localization of specific [3H]dexamethasone binding in urethan-induced mouse lung tumors. Cancer Research 44: 3546-3553, 1984. PMID: 6744279

8. Beer DG, Butley MS, Cunha GR, Malkinson AM: Autoradiographic localization of specific [3H]dexamethasone binding in fetal lung. Dev Biol 105: 351-364, 1984. PMID: 6479444

9. Butley MS, Stoner GD, Beer DG, Beer DS, Mason RJ, Malkinson, AM: Changes in cyclic AMP-dependent protein kinases during the progression of urethan-induced mouse lung tumors. Cancer Research 45:3677-3685, 1985. PMID: 2990675

10. Beer DG, Malkinson AM: A genetic influence on type 2 or clara cell origin of pulmonary adenomas in urethan-treated mice. J Natl Cancer Inst 75: 963-969, 1985. PMID: 3863993

11. Beer DG, Schwarz M, Sawada N, Pitot HC: Expression of H-ras and c-myc protooncogenes in isolated gamma-glutamyl transpeptidase positive rat hepatocytes and in hepatocellular carcinomas induced by diethylnitrosamine. Cancer Research 46: 2435-2441, 1985. PMID: 2870798

12. Thaete LG, Beer DG, Malkinson AM: Genetic variation in the proliferation of murine pulmonary type II cells: basal rates and alterations following urethan treatment. Cancer Research 46: 5335-5338, 1986. PMID: 3756882

13. Schwarz M, Peres G, Beer DG, Maor M, Buchmann A, Kunz W, Pitot HC: Expression of albumin messenger RNA detected by in situ hybridization in preneoplastic and neoplastic lesions in rat liver. Cancer Research 46: 5903-5912, 1986. PMID: 2428487

14. Beer DG, Pitot HC: Biological markers characterizing the development of preneoplastic and neoplastic lesions in rodent liver. Arch Toxicol 10: 68-80, 1986. PMID: 2883960

15. Glauert HP, Beer DG, Reddy JK, Schwarz M, Xu Y, Goldsworthy TL, Coloma J, Pitot HC: Induction of altered hepatic foci by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of dimethylnitrosamine. Cancer Research 46: 4601-4606, 1986.

16. Beer DG, Zweifel KA, Simpson DP, Pitot HC: Specific gene expression during compensatory renal hypertrophy in the rat. J Cell Physiology. 131: 29-35, 1987. PMID: 2883191

17. Beer DG, Neveu MJ, Paul D, Rapp UR, Pitot HC: Expression of the c-raf proto-oncogene and a gap junction protein in preneoplastic foci and rat liver neoplasms. Cancer Research 48: 1610-1617, 1988. PMID: 2894242

18. Pitot HC, Beer DG, Hendrich S: Gene expression during multistage hepatocarcinogenesis. Scand J Gastroenterol (Suppl. 151), 52-61, 1988. PMID: 3227317

19. Beer DG, Pitot HC: Proto-oncogene activation during chemically-induced hepatocarcinogenesis in rodents. Mutation Res 220:1-10, 1989.

20. Beer DG, Neveu MJ: Proto-oncogene and gap junction protein expression in rodent liver neoplasms. Prog Clin Biol Res 331:293-309, 1990.

21. Pan YH, Nuzum EO, Beer DG: K-ras activation and expression in transformed mouse lung cell lines. Mol Carcinogenesis 3: 279-286, 1990.

22. Nuzum EO, Malkinson AM, Beer DG: Specific K-ras activating mutations may determine the development of mouse lung adenomas or adenocarcinomas. Mol Carcinogenesis 3: 287-295, 1990.

23. Hanson LA, Nuzum EO, Jones BC, Malkinson AM, Beer, DG: Expression of the glucocorticoid receptor and K-ras genes in urethan-induced mouse lung tumors and transformed cell lines. Exp Lung Res 17: 371-387, 1991.

24. Stahl BU, Beer DG, Weber LWD, Lebofsky M, Rozman K: Decreased hepatic phosphoenolpyruvate carboxykinase gene expression after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment: implications for the acute toxicity of chlorinated dibenzo-p-dioxins in the rat. Arch Toxicol Suppl. 15, pp. 151-155, 1991.

25. Stahl BU, Beer DG, Weber LWD, Rozman K: Reduction of hepatic phosphoenolpyruvate carboxykinase (PEPCK) activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is due to decreased mRNA levels. Toxicology 79:81-95, 1993.

26. Droms KA, Hanson LA, Malkinson AM, Beer DG: Altered dexamethasone responsiveness and loss of growth control in mouse lung tumor cells. Int J Cancer 53:1017-1022, 1993.

27. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG: Amplification and overexpression of the EGFR and erbB2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213-219, 1993.

28. Wu, GD, Beer DG, Moore JA, Orringer MB, Appelman HD, Traber PG: Sucrase-isomaltase gene expression in Barrett’s esophagus and adenocarcinoma. Gastroenterology 105:837-844, 1993.

29. Li J, Beer DG: K-ras mRNA regulation in nontransformed mouse lung cells. Mol Carcinogenesis 8:193-201, 1993.

30. Mahacek ML, Beer DG, Frank TS, Ethier SP: Finite proliferative lifespan in vitro of a human breast cancer cell strain isolated from a metastatic lymph node. Breast Cancer Research and Treatment, 28:267-276, 1993.

31. Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB, Beer DG: Alterations of K-ras, p53 and erbB2/neu in human lung adenocarcinomas. J Thoracic Cardiovascular Surgery 107:590-595, 1994.

32. Moore JH, Lesser EJ, Erdody DH, Natale RB, Orringer MB, Beer DG: Intestinal differentiation and p53 gene alterations in Barrett’s esophagus and esophageal adenocarcinomas. Int J Cancer 56:487-493, 1994.

33. Wei R-Q, Chen G-H, Beer DG, Kunkel SL, Bolling SF. Inhibition of tumor necrosis factor production by lymphocytes from anti-TNF-treated, cardiac-allographed rats. J Surgical Res 56:601-605, 1994.

34. Bongiorno PF, Al-Kasspooles, Lee SW, Rachwal WJ, Moore JH, Whyte RI, Orringer MB and Beer DG. E-cadherin expression in primary and metastatic neoplasms and in Barrett's esophagus. Br J Cancer 71:166-172, 1995.

35. Rachwal WJ, Bongiorno PF, Ethier SP, Whyte RI, Orringer MB, Beer DG. Expression and activation of erbB2 and EGFR in lung adenocarcinomas. Br J Cancer 72:56-64, 1995.

36. Li J and Beer DG. Effect of increased glucocorticoid responsiveness in transformed mouse lung cells. Mol Carcinogenesis 13:135-145, 1995.

37. Li J, Johnson TA, Hanson LA and Beer DG: Loss of Glucocorticoid-dependent growth inhibition in transformed mouse lung cells. Mol Carcinogenesis 16:213-220, 1996.

38. Johnson TA, Li J, and Beer DG: Influence of glucocorticoid receptor on c-fos inducibilty in activated ras-containing mouse lung cells. Mol Carcinogenesis 17:70-77, 1996.

39. Iannettoni MD, Lee SS, Bonnell MR, Sell TL, Whyte RI, Orringer MB, and Beer DG. The detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53. Ann Thorac Surg 62:1460-1466, 1996.

40. Tsai TT, Bongiorno PF, Orringer MB, Beer DG. Detection of P53 nuclear protein accumulation in esophageal brushings and biopsies. Cancer Detection and Prevention 21(4):326-331, 1997.

41. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinoma. Oncogene 15:1653-1659, 1997.

42. Hughes SJ, Nambu Y, Rehmtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in esophageal adenocarcinomas. Cancer Res 55:5571-5578, 1997.

43. Nambu Y, Hughes SJ, Rehmtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 10:1-9, 1998.

44. Regalado SP, Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Abundant expression of the protein villin in Barrett's esophagus and esophageal adenocarcinomas. Mol Carcinogenesis 22:182-189, 1998.

45. Glover TW, Hoge A, Miller DE, Ascara-Wilke JE, Dagenais SL, Wilke CM, Dierick, and D.G. Beer. The murine FHIT gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res. 58:3409-3414, 1998.

46. Petty EM, Kalikin LM, Orringer MB, Beer DG. Distal chromosome 17q loss in Barrett's adenocarcinomas and gastric cardia adenocarcinomas: Implications for tumorigenesis. Mol Carcinogenesis 22:222-228, 1998.

47. Nambu Y, Iannettoni MD, Orringer MB, Beer DG. Unique expression patterns and alterations in the intestinal protein Villin in primary and metastatic pulmonary adenocarcinomas. Mol Carcinogenesis 23:234-242, 1998.

48. Hughes SJ, Glover TW, Zhu XX, Kuick R. Thoraval D, Orringer MB, *Beer DG, *Hanash S. (*shared senior authorship). A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. Proc Natl Acad Sci (USA) 95:12410-12415, 1998.

49. Soldes OS, Kuick RD, Thomson IA, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG. HSP27 is highly abundant in normal esophagus and markedly diminished in Barrett's metaplasia and esophageal adenocarcinomas. Br. J. Cancer 79:595-603, 1999.

50. MacLennan AJ, Orringer MB, Beer DG. Identification of intestinal-type Barrett's metaplasia by using the intestinal-specific protein villin and esophageal brush cytology. Mol Carcinogenesis 24:137-143, 1999.

51. Hughes SJ, Morse MA, Weghorst CM, Kim H, Watkins PB, Guengerich FP, Orringer MB, Beer DG. Cytochromes P450 is expressed in proliferating cells in Barrett's metaplasia. Neoplasia 1: 145-153, 1999.

52. Compton KR, Orringer MB, Beer DG. Induction of glutathione S-transferase- pi in Barrett's metaplasia and Barrett's adenocarcinoma cell lines. Mol Carcinogenesis. 24:128-136, 1999.

53. Chiang P-W, Beer DG, Wei W-L, Orringer MB, Kurnit DM. Detection of erbB2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res.5:1381-1386, 1999.

54. Lin L, Aggarwal S, Glover TW, Orringer, MB, Hanash S, Beer DG. A minimal critical region of the 8p22-23 amplicon in esophageal adenocarcinomas defined using STS-amplification mapping and quantitative PCR includes the GATA-4 gene. Cancer Res. 60:1341-1347, 2000.

55. Aggarwal S, Taneja N, Lin L, Iannettoni MD, Orringer MB, Rehemtulla A, Beer DG. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of cytochrome C independent of Cox-2 expression. Neoplasia 2 (4) 1-11, 2000.

56. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767-5772, 2000.

57. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads CA, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore M, Danenberg KD, Danenberg PV, Meltzer SJ. Hypermethylated APC DNA in plasma and prognosis in patients with esophageal adenocarcinoma. JNCI 92(22): 1805-1811, 2000.



58. Lin L, Prescott MS, Zhu Z, Singh P, Chun SY, Kuick RD, Hanash S, Orringer, MB, Glover TW, Beer DG. Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res. 60:7021-7027, 2000.

  1. Fang, JM, Arlt MF, Burgess AC, Dagenais SL, Beer DG, Glover TW. Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. Genes, Chromosomes & Cancer 30:292-298, 2001.

  2. Brichory FM, Misek DE, Yim A-M, Krause MC, Giordano TJ, Beer DG, Hanash SM. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci (USA) 98 (17) 9824-9829, 2001.

  3. Brichory FM, Beer DG, Le Naour F, Giordano TJ, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61:7908-7912, 2001.

  4. Oh JMC, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, Tra J, Kardia S, Beer D, Hanash S. A database of protein expression in lung cancer. Proteomics 1:1303-1319, 2001.

  5. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JMG, Lee N, Misek DE, Greenson JK, Kardia SLR, Beer DG, Rennert G, Cho KR, Gruber SB, Fearon ER, S Hanash. Organ-specific molecular classification of lung, colon and ovarian adenocarcinomas using gene expression profiles. Am. J. Pathol. 159:1231-1238, 2001.

  6. Hanash S, Brichory F, Beer DG. A proteomic approach to the identification of lung cancer markers Dis. Markers 17(4):295-300, 2001.

  7. Arlt MF, Miller DE, Beer DG, Glover TW. Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells. Genes, Chromosomes & Cancer 33: 82-92, 2002.

  8. Chen, G, Gharib TG, Huang CC, Taylor JMG, Kardia SLR, Misek DE, Giordano, TJ, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Cellular and Molecular Proteomics 1:304-313. 2002.

  9. Chen, G, Gharib TG, Huang CC, Thomas DG, Sheddon KA, Taylor JMG, Kardia SLR, Misek DE, Giordano, TJ, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Proteomic analysis of proteins overexpressed in lung adenocarcinomas with correlation to mRNA abundance. Clin Cancer Res 8:2298-2305, 2002.

  10. Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Sheddon KA, Misek DE, Thomas DG, Giordano, TJ, Taylor JMG, Yee, J, Orringer MB, Hanash S, Beer DG. Proteomic analysis of cytokeratin isoforms associated with survival in lung adenocarcinoma. Neoplasia 4(5) 440-448, 2002.

  11. Beer DG, Kardia SLR, Huang CC, Misek DE, Lin L, Chen, G, Gharib TG, Giordano, TJ, Thomas DG, Lizyness ML, Kuick R, Taylor JMG, Iannettonni MD, Orringer MB, Hanash S. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nature Medicine 8:816-824, 2002.

  12. Lin L, Miller CT, Contreras JI, Prescott MS, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG. The Hepatocyte Nuclear Factor 3 Alpha FOXA1 (HNF3) gene on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res 62:5273-5279, 2002.

  13. Misek DE, Chang CL, Kuick R, Hinderer R, Giordano TJ, Beer DG, Hanash SM. Oncogenic mutation of the microtubule regulator Op18. Cancer Cell 2(3):217-226, 2002.

  14. Moran CJ, Arenberg DA, Huang CC, Giordano, TJ, Misek DE, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Rantes expression by lung adenocarcinomas is a predictor of survival in stage I patients. Clin Cancer Res 8:3803-3812, 2002.

  15. Creighton C, Hanash S, Beer DG. Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas. FEBS Letters 540:167-170, 2003.

  16. Chen G, Gharib TG, Thomas DG, Huang CC, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash S, Beer DG. Proteomic Analysis of elf-5A in lung adenocarcinomas. Proteomics 3:496-504, 2003.

  17. Chen, G, Gharib TG, Huang CC, Taylor JMG, Kardia SLR, Misek DE, Giordano, TJ, Iannettonni MD, Orringer MB, Hanash S, Beer DG. Oncoprotein 18 is highly expressed in poorly differentiated lung adenocarcinomas and correlates with increased transcription. Mol Cell Proteomics 2(2):107-116, 2003.

  18. Wu R, Lin L, Beer DG, Ellenson LH, Lamb BJ, Rouillard J-M, Kuick R, Hanash S, Cho KR. Amplification and overexpression of L-myc oncogene in ovarian carcinomas. Am. J. Pathol. 165(5):1603-1610, 2003.

  19. Joe AK, Liu H, Xiao D, Soh J-W, Pinto JT, Beer DG, Piazza GA, Thompson WJ, Weinstein IB. Exisulid and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells. J Exp Ther Oncol. 3(2):83-94, 2003.

  20. Chen X, Ning L, Wang S, Wu N, Hong J, Jiao X, Krasna MJ, Beer DG, Yang CS. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. JNCI 95(14):1053-1061, 2003.

  21. Miller CT, Aggarwal S, Lin TK, Contreras JI, Dagenais SL, Orringer MB, Glover TW, Beer DG, Lin L. Amplification and overexpression of the dual-specificity Yak-related kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas indicate a potential oncogenic role in tumorigenesis. Cancer Res. 63: 4136-4143, 2003.

  22. Miller CT, Chen G, Gharib TG, Thomas DG, Misek DE, Giordano TJ, Yee J, Orringer MB, Hanash S, Beer DG. Increased c-crk proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22(39):6006-6013, 2003.

  23. Miller CT, Lin L, Moy JR, Schipper M, Normolle D, Brenner DE, Iannettoni MD, Orringer MB, Beer DG. Gene amplification in esophageal adenocarcinomas and Barrett’s with high-grade dysplasia. Clin. Cancer Res. 9:4819-4825, 2003.

  24. Sheddon KA, Taylor JMG, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR, Gruber S, Logsdon C, Simeone D, Greenson JK, Cho KR, Beer DG, Fearon ER, Hanash S. Accurate Molecular classification of human cancers based on gene expression using a simple classifier with a pathologic tree-based framework. Am. J. Pathol. 163(5):1985-1995, 2003.

  25. Chen G, Gharib TG, Wang H, Huang CC, Thomas DG, Sheddon KA, Misek DE, Taylor JMG, Giordano, TJ, Iannettoni MD, Orringer MB, Hanash S, Beer DG. Protein expression profiles predict patient survival in stage I lung adenocarcinoma. Proc. Natl. Acad. Sci (USA) 100:13537-13542, 2003.

  26. Beer DG. Gene Expression Profiles Predict Survival in Lung Adenocarcinoma. Am. J. Oncol.Rev. 2(5):258-263, 2003.

  27. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash S, Beer DG. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J. Pathol. 204:321-329, 2004.

  28. Lahn M, Chen Su, Shuyu Li, Marcio Chedid, Kimberly R. Hanna, Jeremy R. Graff, George E. Sandusky, Doreen Ma, Clet Niyikiza, Karen L. Sundell, William J. John, Thomas J. Giordano, David G. Beer, Blake M. Paterson, Eric Wen Su, Thomas F. Bumol, Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer, Clinical Lung Cancer, Volume 6, Issue 3, November 2004, Pages 184-189, ISSN 1525-7304, 10.3816/CLC.2004.n.032.

  29. Cuezva JM, Chen G, Alonso A, Isidoro A, Misek DE, Hanash SM, Beer DG. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 25;1157-1163, 2004.

  30. Lin J, Raoof D, Thomas DG, Greenson GK, Giordano TJ, Robinson GS, Barve RA, Orringer MB, Beer DG. L-type amino acid transporter-1 overexpression mediates uptake of melphalan in Barrett’s adenocarcinoma. Neoplasia 6:74-84, 2004.

  31. Gharib TG, Chen G, Huang CC, Misek DE, Iannettoni MD, Orringer MB, Hanash S, Beer DG. Genomic and proteomic analyses of VEGF and IGFBP3 in lung adenocarcinomas. Clin. Lung Cancer 5(5): 307-312, 2004.

  32. Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munshi NC. Growth arrest, apoptosis and telomere shortening of Barrett’s associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 126:1337-1346, 2004.

  33. Moore TC, Jepeal LI, Boylan MO, Singh SK, Boyd N, Beer DG, Chang AJ,Wolfe MM. Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells. Regul. Pept. 120:195-203, 2004.

  34. Daly EB, Chen G, Sun L, Friedlander M, Goldstein D, Beer DG, Chesterman CN, Hogg PJ. Blood level of phosphoglycerate kinase does not correlate with presence or extent of tumour. Int. J. Biol. Markers 19(2):170-2, 2004.

  35. Lin J and Beer DG. Molecular Biology of Upper GI Malignancies. Seminars in Oncology. 31:476-486, 2004.

  36. Lin J, Lin L, Thomas DG, Giordano TJ, Robinson GS, Barve RA, Orringer MB, Beer DG. Melanoma-associated Antigens in Esophageal Adenocarcinoma: Identification of Novel MAGE-A10 Splice Variants. Clin. Cancer Res. 10:5708-5716, 2004.

  37. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WJ, Lubet RA, Yang CS. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of Zileuton and Celecoxib on carcinogenesis. Clin. Cancer Res. 10:6703-6709, 2004.

  38. Chang AC, Beer DG. Lung cancer genomic profiling. Lung cancer: principles and practice 4(4):1-12, 2004.

  39. Lahn M, Su C, Li S, Chedid M, Hanna K, Graff JR, Sandusky GE, Ma D, Niyikaza C, Sundell KL, John WJ, Giordano TJ, Beer DG, Paterson BM, Su W, Bumol TF. Expression levels of protein kinase C-alpha in non-small cell lung cancer. Clinical Lung Cancer 6(3) 184-189, 2004.

  40. Mahidhara RS, Queiroz De Oliveira, Kohout J, Beer DG, Lin J, Watkins SC, Robbins PD, Hughes SJ. Altered trafficing of fas and subsequent resistance to fas-mediated apoptosis occurs by a wild-type p53-independent mechanism in esophageal adenocarcinoma. J Surg Res 123(2):302-311, 2005.

  41. Dobbin K, Beer DG, Meyerson M, Yeatman T, Gerald W, Jacobson J, Conley B, Lugo T, Buetow K, Heiskanen M, Simon R, Minna J, Girard L, Misek D, Kuick R, Taylor J, Hanash S, Golub TR, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann S, Viale A, Giordano T. Inter-laboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res 11:565-572, 2005.

  42. Steiner FA, Hong JA, Guo Z-S, Beer DG, Fischette MR, Chen GA, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS. Sequential decitabine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor (TFPI-2) expression in cancer cells. Oncogene. 2005 Feb 07; [Epub ahead of print]

  43. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Kan T,. Krasna MJ, Beer DG, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene Apr 11; Epub ahead pf print, 24(25) 4138-48, 2005.

  44. Chen G, Bhojani MS, Heaford AC, Chang DC, Griffin L, Yu J, Thomas DG, Giordano TJ, Lin L, Adams D, Orringer MB, Ross BD, *Beer DG, *Rehemtulla A. (*Shared senior authorship). Phosphorylated FADD induces NF-B, cell proliferation, perturbation in cell cycle and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci.USA;102(35):12507-12, 2005.

  45. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang A, Giordano TJ, Glover TW, Beer DG. Genomic amplification of MET with boundaries with Fragile site FRA7G and up-regulation of MET signaling pathways in esophageal adenocarcinomas Oncogene 2005 Sep 26; [Epub ahead of print]

  46. Bhojani MS, Chen G, Ross BD, Beer DG, Rehemtulla A. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 4:11:1476-9, 2005.

  47. W. Zhong, D. Sud, M. Wu, K.A. Merrick, S.D. Merajver, D.G. Beer, and M.-A.Mycek: Sensing cellular function and molecular activity in vivo using fluorescence lifetime imaging microscopy (FLIM), in "Novel Optical Instrumentations for Biomedical Applications II" (C. Depeursinge, Ed.), Proceedings of SPIE-OSA European Conference on Biomedical Optics (ECBO), Vol. 5864 pp 58-66, 2005.

  48. D. Sud, W. Zhong, D.G. Beer, and M.-A. Mycek: Measurement of intracellular oxygen levels using fluorescence lifetime imaging microscopy (FLIM), in "Photon Migration and Diffuse-Light Imaging II" (R. Cubeddu and K. Licha, Eds.), Proceedings of SPIE-OSA European Conference on Biomedical Optics (ECBO), Vol. 5859 pp 7-16, 2005.

  49. Lin L,Wang Z, Prescott MS, van Dekken H, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Gruber SB, Moran JV, Glover TW, Beer DG. Dissection of a 2Mb 3q26.3-q27 segment reveals multiple forms of genetic instability during the development of esophageal adenocarcinoma. Genes, Chromosomes and Cancer 2005 Nov 30; [Epub ahead of print].

  50. Younes M, Georgakis GV, Rahmani M, Beer DG, Albert VR, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer. 2006 Mar 42(4):542-547. Epub 2006 Jan 19

  51. D. Sud, W. Zhong, D. G. Beer, and M. -A. Mycek. Time-resolved optical imaging provides a molecular snapshot of altered metabolic function in living human cancer cell models. Optics Express, 14:4412-4426, 2006.

  52. Fu X, Beer D, Lambeth D, Souza RF, Spechler SJ, Wands J, Behar J, Cao W. cAMP response element binding protein (CREB) mediates acid-induced NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells. J. Biol. Chem 2006 May 17; [Epub ahead of print].

  53. Zhao J, Chang AC, Li C, Shedden KA, Thomas DG, Misek DE, Giordano TJ, Beer DG, Lubman DM. Comparative proteomic analysis of Barrett’s Metaplasia and esophageal adenocarcinomas using 2-D liquid mass mapping. Mol. Cell. Proteomics, Jul 8 [Epub ahead of print], 2006.

  54. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, MacDonald J, Thomas D, Moskaluk C, Wang Y, Beer DG. Gene Expression Signatures for Predicting Prognosis of Squamous Cell Lung Carcinomas. Cancer Research. Aug 1;66(15):7466-7472, 2006.

  55. Yoo C, Zhao J, Pal M, Hersberger K, Huber CG, Simone DM, Beer DG, Lubman DM. Automated integration of Monolith-based protein separation with on-plate digestion for mass spectrometric analysis of esophageal adenocarcinomas. Electrophoresis [Epub ahead of print], August 22, 2006.

  56. Huang C-C, Taylor JMG, Beer DG, Kardia SLR. Hidden Markov model for defining genomic changes in lung cancer using gene expression data. Omics 10(3):276-288, 2006.

  57. McClelland MR, Carskadon S, Zhao L, White ES, Beer DG, Orringer MB, Pickens A, Chang AC, Arenberg DA. Diversity of the angiogenic phenotype in non-small cell lung cancer. Am J Respir Cell Mol Biol. 36:343-350, 2006. PMID: 17079777

  58. Wislez M, Beer DG, Wistuba I, Cadranel J, Saijo N, Johnson BE. Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma: Consensus Conference on Bronchioloalveolar Cell Carcinoma. J. Thoracic Oncology 1(9) S8-S12, 2006. PMID: 17410000

  59. Lin J, Raoof D, Wang Z, Lin M, Thomas DG, Greenson GK, Giordano TJ, Orringer MB, Chang AC, Beer DG, Lin L. Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C (UBE2C) in esophageal adenocarcinoma. Neoplasia, Dec;8(12):1062-1071, 2006. PMID: 17217624

  60. Chen G, Wang X,Yu J, Varambally S, Yu J, Thomas DG, Wang Z, Fielhauer J,Ghosh D, Giordano TJ, Chang AC, Orringer MB, *Beer DG, *Chinnaiyan AM, (*Shared senior authorship). Epitomic profiles of humoral immune response associated with diagnosis and prognosis of lung adenocarcinomas. Cancer Research 2007 Apr 1;67(7):3461-7. PMID: 17409457

  61. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Cao W. NADPH oxidase NOX5-S mediates acid-induced Cox-2 expression via NF-kB activation in Barrett's esophageal adenocarcinoma cells. J. Biol. Chem., [Epub ahead of print]. Apr 2, 2007. PMID: 17403674

  62. Si J, Fu X, Behar J, Wands J, Beer DG, Lambeth D, Chin E, Cao W. STAT5 mediates Platelet-Activating Factor NADPH oxidase NOX5-S expression in Barrett's esophageal adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2007 Oct 18; [Epub ahead of print]. PMID: 17947454

  63. Jin Z, Mori Y, Yang J, Sato F, Ito T, Cheng Y, Paun B, Hamilton JP, Kan T, Olaru A, David S, Agarwal R, Abraham JM, Beer D, Montgomery E, Metlzer SJ. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007 Sep 20;26(43):6332-40. Epub 2007 Apr 23. PMID: 17975140

  64. Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Metlzer SJ. Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res. 2007 Nov 1;13(21):6293-300. PMID: 18199717

  65. Weir BA, Getz G, Woo MS, Perner S, Beroukhim R, Ding L, Lin WM, Province MA, Kraja A, Johnson L, Shah K, Thomas RK, Barletts JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar A, Giordano T, Greulich H, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna J, Morgan MB, Nadel M, Orringer MB, Osbourne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Sato M, Shepard F, Spitz MR, Tsao M-S, Twoney D, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis W, Pao W, Rubin MA, Gabriel S, Gibbs R, Varmus H, Wilson RK, Lander E, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007 Nov 4(Epub ahead of print). PMID: 18641660

  66. Wang S, Nan B, Zhu J, Beer DG. Doubly penalized Buckley-James method for survival data with high-dimensional covariates. Biometrics 2007 Aug 3; [Epub ahead of print]. PMID: 17680828

  67. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R, Abraham JM, Metlzer SJ. Hypermethylation of the AKAP12 Promoter is a Biomarker of Barrett's-Associated Esophageal Neoplastic Progression. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7. PMID: 18199717

  68. DiFeo A, Feld L, Beer DG, Martignetti JA, Narla G. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 2008 Feb 4; [Epub ahead of print] PMID: 18250346

  69. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008 Mar;10(3):298-302. PMID: 18320074

  70. Shedden K, Taylor JMG, Enkemann SA, Tsao MS, Yeatman TJ, Eschrich S, Jurisica I, Gerald WL, Venkatraman ES, Meyerson M, Kuick R, Dobbin KK, Lively T, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Sharma A. Jacobson JW, Beer DG. Gene Expression-Based Survival Prediction in Lung Adenocarcinoma: A Multi-Site, Blinded Validation Study Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Nature Medicine July 20, 2008(Epub ahead of print). PMID: 18641660

  71. Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Beer DG, Nagatsuka H, Tanaka N, Naomoto Y.Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res. 2008 Jul15;14(14):4631-9. PMID: 18628478

  72. Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK.Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 1;14(15):4971-80. PMID: 18676772

  73. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ. Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer. 2008 Nov 15;123(10):2331-6. PMID: 18729198

  74. Albertus DL, Seder CW, Chen G Wang X, Hartojo W, Lin L, Silvers A, Thomas DG, Giordano TJ, Chang AC, Orringer MB, Bigbee WL, Chinnaiyan AM, Beer DG. AZGP1 expression is epigenetically regulated and its autoantibody predicts survival in lung adenocarcinoma. J. Thoracic Oncology 2008 Nov;3(11):1236-1244. PMID: 18978557

  75. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence M, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good P, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008 Oct 23;455(7216):1069-75. PMID: 18948947

  76. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, Castranova V, Beer DG, Qian Y. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res. 2008 Dec 15;14(24):8213-20. PMID: 19088038

  77. Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen G,Chang AC, Orringer MB, Beer DG. INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. J. Thoracic Oncology. 2009 Feb 23. [Epub ahead of print] PMID: 19240652

  78. Seder CW, Hartojo W, Lin L, Silvers A, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. Upregulated INHBA Expression May Promote Cell Proliferation and Is Associated with Poor Survival in Lung Adenocarcinoma. Neoplasia. 2009 Apr;11(4):388-96. PMID: 19308293

  79. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Research. 2009; 69: (14). July 15, 2009 5776-5783.

  80. Kausar T, Ahsan A, Hasan Md.R, Lin L,Beer DG, Ralhan R. Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2009 Aug 14. [Epub ahead of print] PMID: 19685492

  81. Ramos AH, Dut A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Steidl A-C, Tanaka K, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna J, Chirieac L, Lindeman N, Giordano TG, Beer DG, Wagner P, Wistuba I I, Rubin MA, Meyerson M. Amplification of Chromosomal Segment 4q12 in Non-small Cell Lung Cancer. Cancer Biol Ther. 2009 Nov;8(21):2042-50. Epub 2009 Nov 7.PMID: 19755855

  82. Hassan KA, Chen G, Kalemkerian GP, Wicha M, Beer DG. An embryonic stem cell–like signature identifies poorly-differentiated lung adenocarcinoma but not squamous carcinoma. Clin Cancer Research 2009 Oct 15;15(20):6386-90. Oct 6. PubMed PMID: 19808871.

  83. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X,

Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from

paired-end sequencing data in cancer. Nat Biotechnol. 2009 Nov;27(11):1005-11.

Epub 2009 Nov 1. PubMed PMID: 19881495; PubMed Central PMCID: PMC2903743.


  1. Bass A, Watanabe H, Yul S, Mermel C, Perner S, Verhaak R, Kim SY, Wardell L, Tamayo P Gat-Viks I, Ramos A, Woo MS, Weir B, Gets G, Beroukhim R, O’Kelly M, Dutt A, Rozenbaltt-Rozen O, Dziunycz P, Komisarof J, Chirieac L, LaFargue V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Brose M, Ribeiro U, Marie SK, Shivdasanil RA, Tsao MS, Rubin M, Wong K, Regev A, Hahn WC, Beer DG, Rustgi A, Meyerson M. SOX2 is an Amplified Oncogene in Squamous Cell Esophageal and Lung Carcinomas. Nature Genetics Nov;41(11):1238-42. Epub 2009 Oct 4. PubMed PMID: 19801978.

  2. Beroukhim R, Mermel CH, D Porter, G Wei, S Raychaudhuri, J Donovan, J Barretina1, JS Boehm, J Dobson, M Urashima, K McHenry, R Pinchback, AH Ligon, J Cho, L Haery, H Greulich, M Reich, W Winckler, BA Weir, K Tanaka, DY Chiang, AJ Bass, A Loo, C Hoffman, J Prensner, T Liefeld, D Yecies,nS Signoretti, E Maher, FJ Kaye, H Sasaki, JE Tepper, JA Fletcher, J Baselga, M Tsao, MA Rubin, PA Janne, MJ Daly, C Nucera, RL Levine, BL Ebert, S Gabriel, AK Rustgi, CR Antonescu, M Ladanyi, A Leta, LA Garraway, M Loda, DG Beer, LD True, A Okamoto, SL Pomeroy, S Singer, ES Lander, G Getz, TR Golub, WR Sellers, M Meyerson. The landscape of copy number alterations across multiple human cancers. Nature. 2010 Feb 18;463(7283):899-905.PMID: 20164920

  3. Boonstra JJ, van Marion R, Beer DG , Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H , ShimadaY, van Dekken H, Tilanus HW, Dinjens WNM. Contaminated Cell Lines Threaten the Development of Treatment Strategies for Esophageal Adenocarcinoma. J. Natl. Cancer Inst. 2010 Feb 24;102(4):271-4. Epub 2010 Jan 14.PMID: 20075370

  4. AL Silvers, L Lin, AJ Bass, Z Wang, G Chen, DG Thomas, J Lin, M Meyerson, DG Beer, AC. Chang. Decreased selenium binding protein 1 (SELENBP1) in esophageal adneocarcinoma results from post-transcriptional and epigenetic mechanisms and affects chemosensitivity. Clin Cancer Res. 2010 Apr 1;16(7):2009-21. Epub 2010 Mar 23.PMID: 20332323

  5. Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, Rao H, Wang Z, Greenson JK,

Giordano TJ, Orringer MB, Rehemtulla A, Bhojani MS, Beer DG, Chang AC. Curcumin

promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor

kappaB in esophageal adenocarcinoma. Transl Oncol. 2010 Apr;3(2):99-108. PubMed

PMID: 20360934; PubMed Central PMCID: PMC2847317.



  1. Li M, Anastassiades CP, Joshi B, Komarck CM, Piraka C, Elmunzer BJ, Turgeon

DK, Johnson TD, Appelman H, Beer DG, Wang TD. Affinity Peptide for Targeted

Detection of Dysplasia in Barrett's Esophagus. Gastroenterology. 2010 Nov;139(5):1472-80. PMID: 20637198.



  1. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M, Arima C, Travis

WD, Yatabe Y, Takahashi T, Brambilla E, Beer DG. Clinically relevant

characterization of lung adenocarcinoma subtypes based on cellular pathways: an

international validation study. PLoS One. 2010 Jul 22;5(7):e11712. PubMed PMID:

20661423; PubMed Central PMCID: PMC2908611.



  1. King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N. The vitamin D/CYP24A1

story in cancer. Anticancer Agents Med Chem. 2010 Mar;10(3):213-24. Review.

PubMed PMID: 20184548.



  1. Qazi A, Pai J, Maitah M, Fulciniti M, Pelluru D, Nanjappa P, Batchu RB, Prasad M, Bryant CS, Rajput S, Gryznov S, Goyal RK, Beer DG, Weaver DW, Munshi NC, Shammas MA. Anticancer activity of a broccoli derivative, sulforaphane, in Barrett's adenocarcinoma: Potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010 Dec 1;3(6):389-99.PMID: 21151478.

  2. G Chen, SH Kim, A King, Lili Zhao, PJ Christensen, Z Wang, DE Brenner, RU Simpson, and DG Beer, N Ramnath. CYP24A1 mRNA Expression Is Independently Prognostic for Outcome in Lung Adenocarcinoma. Clin Cancer Res. 2010 Dec 17. [Epub ahead of print] PMID: 21169243

  3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85. PubMed PMID: 21252716.

  4. Meng H, Chen G, Zhang X, Wang Z, Thomas D, Giordano T, Beer DG, Wang MM. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res. Mar21, 2011 Epub ahead of print. PMID: 21325077.

  5. Pal J, Bertheau R, Buon L, Qazi A, Batchu RB, Bandyopadhyay S, Ali-Fehmi R, Beer DG, Weaver DW, Reis RS, Goyal RK, Huang Q, Munshi NC, Shammas MA. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene. 2011 Mar 21.

[Epub ahead of print] PubMed PMID: 21423218.

  1. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK,

Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Apr 3;1(1):78-89. PubMed PMID: 22328973; PubMed Central PMCID: PMC3274752.

  1. Ray D, Ahasan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia 7:570-578, 2011. PMID: 21750651

  2. Suzuki K, SS Kachala, K Kadota, R Shen, DG Beer, VW Rusch, WD Travis, PS Adusumilli. Prognostic Immune Markers in Non-Small Cell Lung Cancer. Clin Cancer Res. Aug 15;17(16):5247-56. Epub 2011 Jun 9. 2011. PubMed PMID: 21659461.

  3. Chen G, Kim S, Taylor JMG ,Wang Z, Lee O, Ramnath N, Reddy RM , Lin J, Chang AC, Orringer MB, Beer DG. Development and validation of a qRT-PCR classifier for lung cancer prognosis. J. Thoracic Oncology Sep;6(9):1481-7, 2011. PMID: 21792073.

  4. H Gong, S Wang, G Mayer, G Chen, A Stepanova, E Webster, G Leesman, S Singh, DG Beer. Signatures of Drug Sensitivity in Non-Small Cell Lung Cancer. International Journal of Proteomics, Vol. 2011. 2011;2011:215496. Epub 2011 Aug 7.PMID:22091388

  5. Lin J, Beer DG. Molecular Predictors of Prognosis in Lung Cancer. Review Article. Annals of Surgery 2011 Aug 6. [Epub ahead of print].PMID: 21822554.

  6. Chen G, Beer DG. Response to translating cancer complexity to clinical decisions. J Thorac Oncol. 2011 Sep;6(9):1456-7.

  7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Powell CA, Beer DG, Riely GJ, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Gould M. International Association for the Study of Lung Cancer/American Thoracic Society/European RespiratorySociety: International Multidisciplinary Classification of Lung Adenocarcinoma: An Executive Summary. Proc Am Thorac Soc Vol 8. pp 381–385, 2011.PMID: 21926387

  8. WW Lockwood, KL Thu, L Lin, LA Pikor, R Chari, WL Lam, DG Beer. Integrative Genomics Identified RFC3 as an Amplified Candidate Oncogene in Esophageal Adenocarcinoma Clin Cancer Res. 2012 Apr 1;18(7):1936-46. 2012 Feb 10. [Epub ahead of print]PMID: 22328562

  9. Y-W Wan, DG. Beer, NL Guo Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma. Lung Cancer 2011 Oct 31. [Epub ahead of print]PMID: 22047960

  10. Lin L, Bass A, Lockwood WW, Wang Z, Silvers AL, DG Thomas, Li W, Chang AC, Orringer MB, Glover TW, Giordano TJ, Lam W, Meyerson M, Beer DG. Activation of GATA6 sustains oncogenic survival in esophageal adenocarcinoma. PNAS Feb 28, 2012 [Epub ahead of print] PMID: 22375031

  11. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, Bass AJ, Godfrey TE, Litle

VR. Comparative genomics of esophageal adenocarcinoma and squamous cell

carcinoma. Ann Thorac Surg. 2012 Apr;93(4):1101-6. PubMed PMID: 22450065.



  1. Kim SH, G Chen, AN King, CK Jeon, PJ Christensen, L Zhao, RU Simpson, DG Thomas, TJ Giordano, DE Brenner, B Hollis, DG Beer, N Ramnath.Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer May 5 2012 Epub ahead of print. PMID: 22564359

  2. Dulak AM, S Schumacher, J van Lieshout, Y Imamura, C Fox, B Shim, A Ramos, G Saksena, S Baca, J Baselga, J Tabernero, J Barretina, P Enzinger, G Corso, F Roviello, L Lin, S Bandla, J Luketich, A Pennathur, M Meyerson, S Ogino, RA Shivdasani, DG Beer, TE Godfrey, R Beroukhim, AJ Bass. Genomic analysis of esophageal, gastric, and colorectal adenocarcinomas demonstrates distinct patterns of genome instability and oncogenic events. Cancer Res. 2012 Sep 1;72(17):4383-4393. Epub 2012 Jul 2.PMID:

22751462.

  1. Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, Imoto S, Saito A, Ueno K, Hatanaka Y, Yoshida R, Higuchi T, Nomura M, Beer DG, Yokota J, Miyano S, Gotoh N. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.PLoS One. 2012;7(9):e43923. PMID: 23028479.

  2. Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD,Schultz N, …..Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.PMID:22960745

  3. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha M. Notch pathway activity identifies functional lung cancer stem cells and correlates with worse survival. Clin Cancer Res. 2013 Feb 26. [Epub ahead of print]PMID:

23444212

  1. Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and

Participating Institutions. Effect of tumor size on prognosis in patients treated

with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An

analysis of the staging project database of the International Association for the

Study of Lung Cancer. J Thorac Oncol. 2013 Mar;8(3):315-21.PubMed PMID: 23334092.



  1. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura

Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A,

Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC,

Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R,

Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG,

Godfrey TE, Getz G, Bass AJ. Exome and whole-genome sequencing of esophageal

adenocarcinoma identifies recurrent driver events and mutational complexity. Nat



Genet. 2013 Mar 24. [Epub ahead of print] PubMed PMID:23525077.

  1. Lin J, Beer DG. Update on recent prognostic markers in adenocarcinoma. Lung Cancer Management (2013) 2(2), 141–152.

  2. Sturm MB, BP Joshi, S Lu,C Piraka, BJ Elmunzer RS Kwon, YC Chen, J Zhou, DG Beer, H Appelman, DK Turgeon, TD Wang. Targeted imaging of esophageal neoplasia with fluorescent-labeled peptide: first in-humans results. Science Translational Medicine 2013 May 8;5(184):184ra61. doi: 10.1126/scitranslmed.3004733.PMID:23658246.

  3. S Rousseaux, A Debernardi, B Jacquiau, A-L Vitte, A Le Bescont, A Vesin, H Mignotte, D Moro-Sibilot, P-Y Brichon, S Lantuejoul, M Callanan, DG Beer, J-F Timsit, C Brambilla, E Brambilla, S Khochbin. Germline-like nature of aggressive metastasis-prone lung cancer cells. Science Translational Medicine 2013 May 22;5(186):186ra66.

  4. C Man-Chung Li, G Chen, T Dayton, C Kim-Kiselak, S Hoersch, CA Whittaker, RT Bronson, DG Beer, MM Winslow, T Jacks. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes and Development 2013 Jul 15;27(14):1557-67.

  5. Sandoval J, J Mendez-Gonzalez, E Nadal, G Chen, FJ Carmona, S Sayols, S Moran, H Heyn, M Vizoso, A Gomez, M Sanchez-Cespedes, Y Assenov, F Müller, C Bock, M Taron, J Mora, LA Muscarella, M Pollan, LM Montuenga, E Brambilla, JK Field, L Roz, GV Scagliotti, R Rosell, DG Beer, M Esteller. A Prognostic DNA Methylation Signature for Stage I Non-Small Cell lung Cancer. J. Clin. Oncol. (in press)

  6. Shukla S, US Allam, A Ahsan, PM Krishnamurthy, K Marsh, M Rumschlag, G Chen, S Shankar, C Whitehead, M Schipper, V Basrur, DR Southworth, A, Chinnaiyan, A Rehemtulla, DG Beer, TS Lawrence, MK Nyati, D Ray. Mutant KRAS protein stability and GTPase activity is regulated by SMURF2-UBCH5 complex mediated ubiquitination. (submitted).

  7. Nadal E, G Chen, M Gallegos, L Lin, D Ferrer-Torres, A Truini, Z Wang, J Lin, RM Reddy, R Llatjos, I Escobar, J Moya, AC Chang, F Cardenal, G Capella, DG Beer. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early stage lung adenocarcinoma. Clin Cancer Res. (resubmitted).

  8. Cancer Genome Atlas Research Network. Diversity of Lung Adenocarcinoma Revealed by Integrative Molecular Profiling. Nature (submitted).

  9. Grabauskiene S, Bergeron E, Chen G, Chang AC, Lin J, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM. CHK1 Levels Correlate with Sensitization to Pemetrexed by CHK1 Inhibitors in Non-Small Cell Lung Cancer Cells. (submitted).

  10. Balbin OA, J Prensner, A Sahu, A Yocum, S Shankar, R Malik, D Fermin, M Dhanasekaran, B Chandler, D Thomas, DG Beer, X Cao, AI Nesvizhski, AM Chinnaiyan. Reconstructing targetable pathways in lung cancer by integrating transcriptome, proteome and phosphoproteome. (submitted).

  11. Li H, M Tan, L Jia, D Wei, Y Zhao, G Chen, L Zhao, D Thomas, DG Beer, and Y Sun. Inactivation of Sag/Rbx2/Roc2 E3 ligase suppresses KrasG12D-driven lung cancer via blockage of NFB and mTOR. (submitted).

  12. Khan A, Bhojani M, Nyati S, Hamilton C, Coppola J, Chen G, Thomas D, Rao H, Zhang L, Beer DG, Ross B, Rehemtulla A. Fas-associated Death Domain is a critical mediator of EGFR-induced induced NF-κB activation. (submitted).

  13. Ramnath N, AN King, W Chen, A Wenzlaff, AG Schwartz, DG Beer and ML Cote. Genetic Variants of Vitamin D3 Pathway Related-Genes and Non-Small Cell Lung Cancer (NSCLC) Risk in Women (submitted).

  14. Saintigny P, L Zhang, L Girard, L Xu, LA Byers, HN Kadara, YH Fan, JJ Lee, K Coombes, DC Lam, PL Chung, MP Wong, WL Gerald, DG Beer, H Shigematsu, M-S Tsao, FA Shepherd, SM. Lippman, RS Herbst, ES Kim, L Mao, WK Hong, I Wistuba, J Minna, JV Heymach. An EGFR mutation signature is prognostic in EGFR wild-type lung adenocarcinomas and identifies MACC1 as an EGFR mutant-associated regulator of MET (submitted).

  15. Zhanga Y, R Caladob, AK Meekerc, M Raoa, JA Hong, S Ataya, P Mccormick, SH Garfield, D Wangj, H Padilla-Nash, M Zhang, TF Kunst, NR Peterson, F Liu, S Xia, S Inchauste, NK Altorki, AG Casson, DG Beer, CC Harris, T Ried, NS Young, DS Schrump. A Non-synonymous Telomerase Variant Identified in Esophageal Carcinomas Facilitates Telomere Shortening and Inhibits Non-Canonical Telomerase Activity in Cancer Cells (submitted).

  16. Ramnath N, CK Jeon, Colancino J, Rozedk LS, Christensen PJ, Beer DG, SH Kim. Epigenetic regulation of Vitamin D 24-hydroxlyase (CYP24A1) in human lung adenocarcinoma. (submitted).

  17. Zhang Z, H Shiratsuchi, J Lin, G Chen, RM Reddy, AC Chang, DM Simeone, MS Wicha, DG Beer, N Ramnath, S Nagrath.Isolation and ex-vivo expansion of circulating tumor cells in early lung cancer using an in-situ organotypic microfluidic co-culture model.(submitted).

Book Chapters

1. Pitot HC, Beer DG, Hendrich S: Multi-stage carcinogenesis of the rat hepatocyte. Banbury Report 25: 41-53, 1987.

2. Pitot HC, Beer DG, Hendrich S: Multi-stage carcinogenesis: the phenomenon underlying the theories. In: Iversson, O. (ed). Theories of Carcinogenesis. (Hemisphere Publishing Co., New York, 158-177, 1988.

3. Hanash SM, Richardson B, Kuick R, Wimmer K, Thoraval DH, Lamb B, Nambu Y and Beer DG. DNA methylation changes in lung cancer. Clinical and Biological Basis of Lung Cancer Prevention, (Y. Martinet, F.R. Hirsch, N. Martinet, J.-M. Vignaud and J.L. Mulshine eds.) Birkhauser Verlag, Basel Switzerland, pp 157-167, 1997.

4. Hanash SH, Richardson B, Beer DG. Relevance of DNA methylation to lung cancer. In: Lung tumors: Fundamental Biology and Clinical Management, Brambilla, Brambilla (eds.) New York: Marcel Dekker, Inc., Vol 124, pp227-235, 1999.

5. Beer DG, Stoner GD. In: Clinics. Clinical models of chemoprevention: The esophagus. W.B. Saunders Company, Philadelphia, Pennsylvania, Vol 12, (5), pp. 1055-1077, 1998.



  1. Nambu Y, and Beer DG. In: Lung Cancer, Methods in Molecular Medicine, Humana Press, USA, “Altered surface markers in lung cancer: Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinoma may allow escape from immune surveillance: 74: 259-266, 2003.

  2. Beer DG. Molecular Prognostication of Lung Cancer, Lippincott Williams & Wilkins, HI Pass, DP Carbone, DH Johnson, JD Minna, AT Turrisi eds. pp 270-280, 2005.

  3. Beer DG. Gene Expression Analyzes of Lung Cancer: Clinical Challenges and Opportunities. Methods of Microarray Data Analysis III

    Download 352.96 Kb.

    Share with your friends:
1   2   3



The database is protected by copyright ©ininet.org 2024
send message
    Main page
national academy